NEW YORK, Jan. 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diagnostics Partnering Terms and Agreementshttp://www.reportlinker.com/p0765263/Diagnostics-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics
Report description The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all diagnostics partnering deals announced since January 2007, including financial terms where available, including over 2,900 links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading diagnostics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.
Key benefits Diagnostics Partnering Terms and Agreements provides the reader with the following Key benefits:• In-depth understanding of diagnostic deal trends since 2007
• Analysis of the structure of diagnostic agreements with numerous real life case studies
• Comprehensive access to over 2,900 actual diagnostic contracts entered into by the world's biopharma companies
• Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a diagnostic agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.Diagnostics Partnering Terms and Agreements includes: o Trends in diagnostic dealmaking in the biopharma industry since 2007o Analysis of diagnostic deal structure
o Case studies of real-life diagnostic deals
o Access to over 2,900 diagnostic contract documents
o The leading diagnostic deals by value since 2007
o Most active diagnostic dealmakers since 2007
o The leading diagnostic partnering resources
In Diagnostics Partnering Terms and Agreements, the available contracts are listed by:
o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target
Each deal title links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The Diagnostics Partnering Terms and Agreements report provides comprehensive access to available contract documents for over 2,900 diagnostic deals. Analyzing actual contract agreements allows assessment of the following:
o What are the precise diagnostic rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Executive Summary Chapter 1 – IntroductionChapter 2 – Trends in diagnostic dealmaking2.1. Introduction2.2. Diagnostic partnering over the years2.3. Most active diagnostic dealmakers2.4. Bigpharma diagnostic dealmaking activity2.5. Bigpharma not active in diagnostics2.6. Diagnostics partnering by deal type2.7. Diagnostics partnering by stage of development2.8. Diagnostics partnering by disease type2.9. Average deal terms for diagnostics partnering2.9.1 Diagnostics partnering headline values2.9.2 Diagnostic deal upfront payments2.9.3 Diagnostics royalty rates2.10. The anatomy of diagnostic partnering2.10.1. The anatomy of a diagnostic deal2.10.1.a. Case study 1: Sequenom – Lenetex – January 20072.10.1.b. Case study 2: Celera – Siemens Medical Solutions – July 20072.10.1.c. Case study 3: US Genomics – Rosetta Genomics – May 20062.11. Litigation and settlement in diagnostics
Chapter 3 – Leading diagnostic deals
3.1. Introduction3.2. Top diagnostic deals by value3.3. Top diagnostic deals involving bigpharma3.4. Leading diagnostics M&A deals by value
Chapter 4 – Bigpharma diagnostic deals
4.1. Introduction4.2. How to use bigpharma diagnostic partnering deals4.3. Bigpharma partnering company profilesAbbottActavisAlcon LabsAllerganAmgenApotexAstellasAstraZenecaBaxter InternationalBayerBiogen IdecBoehringer IngelheimBristol-Myers SquibbCelgeneCephalonChugaiCSLDaiichi SankyoDainippon SumitomoEisaiEli LillyForest LaboratoriesGenzymeGilead SciencesGlaxoSmithKlineHospiraJohnson & JohnsonKyowa Hakko KirinLundbeckMenariniMerck & CoMerck KGaAMitsubishi TanabeMylanNovartisNovo NordiskNycomed PharmaOtsukaPfizerRocheSanofiServierShionogiShireStadaTakedaTevaUCBWarner ChilcottWatson
Chapter 5 – Diagnostic dealmaking directory
5.1. Introduction5.2. By stage of developmentDiscoveryPre-clinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulation5.3. By deal typeAsset purchaseAssignmentBigpharma outlicensingCo-developmentCollaborative R&DCo-marketContract serviceCo-promotionCRADACross-licensingDevelopmentDistributionEquity purchaseEvaluationGrantInterestsJoint ventureLicensingLitigationLoanManufacturingManufacturing - OEMMarketingMaterial transferOptionPromotionResearchRoyalty financingSettlementSpin outSub-licenseSupplyTechnology transferTerminationWarranty5.4. By therapy areaCardiovascularCentral Nervous SystemDentalDermatologyGastrointestinalGenetic disordersGenitourinaryHematologyHormonalHospital careImmunologyInfectivesInflammatoryMetabolicMusculoskeletalOncologyOphthalmicsRespiratorySensory organsChapter 6 – Diagnostic partnering resource center
6.1. Online diagnostic partnering 6.2. Diagnostic partnering events6.3. Further reading on diagnostic dealmaking
Appendices
Appendix 1 – Deal type definitionsAppendix 2 – Example diagnostics partnering agreement About CurrentPartneringRecent titles from CurrentPartnering
Order Form – Reports
Table of figuresFigure 1: Diagnostic partnering since 2007Figure 2: Most active diagnostic dealmakers 2007-2011Figure 3: Bigpharma – top 50 – diagnostic deals 2007 to 2011Figure 4: Bigpharma diagnostic deal frequency – 2007 to 2011Figure 5: Inactive bigpharma in diagnostic dealmaking 2007-2011Figure 6: Diagnostics partnering by deal type since 2007Figure 7: Diagnostics partnering by stage of development since 2007Figure 8: Diagnostics partnering by disease type since 2007Figure 9: Diagnostics partnering by oncology target since 2007Figure 10: Diagnostic deals with a headline value – by stage of developmentFigure 11: Diagnostic deal headline value distribution – discovery stage, US$millionFigure 12: Diagnostic deal headline value distribution – discovery stage, US$million - detailFigure 13: Diagnostic deal headline value distribution – preclinical stage, US$millionFigure 14: Diagnostic deal headline value distribution – preclinical stage, US$millionFigure 15: Diagnostic deals with upfront payment values – by stage of developmentFigure 16: Diagnostic deal upfront payment distribution – discovery stage, US$millionFigure 17: Diagnostic deal upfront payment distribution – discovery stage, US$million - detailFigure 18: Diagnostic deals with milestone paymentsFigure 19: Diagnostic deal milestone payment distribution, US$millionFigure 20: Diagnostic deals with royalty ratesFigure 21: Components of the typical diagnostic deal structureFigure 22: Settlement licensing agreements since 2003Figure 23: Top diagnostic deals by value since 2007Figure 24: Top diagnostic deals signed by bigpharma value since 2007Figure 25: Top diagnostic M&A deals by value since 2007Figure 26: Diagnostic deals by therapy – cardiovascular – 2007 - 2011Figure 27: Diagnostic deals by therapy – central nervous system – 2007 - 2011Figure 28: Diagnostic deals by therapy – dental – 2007 - 2011Figure 29: Diagnostic deals by therapy – dermatology – 2007 - 2011Figure 30: Diagnostic deals by therapy – gastrointestinal – 2007 - 2011Figure 31: Diagnostic deals by therapy – genetic disorders – 2007 - 2011Figure 32: Diagnostic deals by therapy – genitourinary – 2007 - 2011Figure 33: Diagnostic deals by therapy – hematology – 2007 - 2011Figure 34: Diagnostic deals by therapy – hormonal – 2007 - 2011Figure 35: Diagnostic deals by therapy – hospital care – 2007 - 2011Figure 36: Diagnostic deals by therapy – immunology – 2007 - 2011Figure 37: Diagnostic deals by therapy – infectives – 2007 - 2011Figure 38: Diagnostic deals by therapy – inflammatory – 2007 - 2011Figure 39: Diagnostic deals by therapy – metabolic – 2007 - 2011Figure 40: Diagnostic deals by therapy – musculoskeletal – 2007 - 2011Figure 41: Diagnostic deals by therapy – oncology – 2007 - 2011Figure 42: Diagnostic deals by therapy – ophthalmics – 2007 - 2011Figure 43: Diagnostic deals by therapy – respiratory – 2007 - 2011Figure 44: Diagnostic deals by therapy – sensory organs – 2007 - 2011Figure 45: Online partnering resourcesFigure 46: Forthcoming partnering eventsFigure 47: Deal type definitionsFigure 48: Diagnostics partnering agreement between Inhibitex and 3M, February 2007To order this report:Diagnostics Industry: Diagnostics Partnering Terms and Agreements
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article